中西医结合治疗慢性肺心病急性发作期并发多功能脏器衰竭的临床疗效

The Clinical Effect of Chinese and Western Medicine in the Treatment of Patients with Multiple Organ Failure in Acute Exacerbation of Chronic Pulmonary Heart Disease

目的:为了进一步研究和探讨临床治疗慢性肺心病实践过程中的有效治疗方法,从而为临床治疗慢性肺心病的实践提供临床依据。方法:本文以本院2010年12月-2012年12月期间入院治疗的142例慢性肺心病患者为研究对象,按照患者实施临床治疗方法的不同将其分成中西医结合治疗组74例和对照组68例,对照组采用西医基础治疗,治疗组在上述治疗的同时加用中药治疗,观察比较两组患者实施不同临床治疗方法后的临床治疗效果和住院时间。结果:中西医结合治疗组的治愈好转率为64.86%,对照组为47.06%,两组比较差异有统计学意义(P<0.05)。说明中西医结合治疗组的疗效显著优于对照组。中西医结合治疗组患者的平均住院时间为(22.43±3.34)d,对照组为(27.99±4.56)d,两组比较差异有统计学意义(P<0.05)。结论:在临床针对慢性肺心病治疗的实践过程中,采用中西医结合治疗方法的临床治疗效果显著,患者的死亡率较低,是临床治疗慢性肺心病的可靠选择。

Objective：To further study and explore the effective methods in the treatment of chronic pulmonary heart disease in clinical practice and to provide the clinical basis for the clinical treatment of chronic pulmonary heart disease.Method：One hundred and forty-two cases of chronic pulmonary heart disease in the hospital from December 2010 to December 2012 were chosen as the research objects. All patients were randomly divided into western medicine combined treatment of TCM group（74 cases）and control group（68 cases）. The control group was treated by the basic treatment of western medicine,while the treatment group was treated by western medicine combined traditional Chinese medicine treatment. The clinical efficacy of the two groups in patients with different clinical treatment and hospitalization time were compared. Result：The effective rate of the control group was 47.06%while the treatment group was 64.86%after treatment,and the difference between the two groups were statistically significant（P〈0.05）. The hospitalization time of the control group was（27.99±4.56）d while the treatment group was（22.43±3.34）d,and the difference between the two groups were statistically significant（P〈0.05）.Conclusion：In the clinical practice for the treatment of chronic pulmonary heart disease,the clinical therapeutic effect of traditional chinese with western medicine is significant,the mortality rate is low,and it is a reliable choice for the clinical treatment of chronic pulmonary heart disease.